| Ytd | -25.62% | |
| 1y | -34.07% |
| Open | 6.55 | Prev Close | 6.57 | Low | 6.53 | High | 6.62 | Mkt Cap | 622.04M |
| Vol | 42.21K | Avg Vol | 78.43K | EPS | -2.06 | P/E | N/A | Forward P/E | -7.21 |
| Beta | 1.02 | Short Ratio | 1.22 | Inst. Own | 1.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 5.93 | 200-d Avg | 7.28 | 1yr Est | 15.85 |
VALN News
Benzinga readers can review the latest analyst takes on high-yielding stocks in health care sector.
Stock futures mixed, Nasdaq 100 down 100 points. Applied Optoelectronics falls after announcing $600
Valneva (VALN) is transitioning from a low-margin vaccine manufacturer to a high-margin royalty and
Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc. (N
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euro
NEW YORK & LYON, France, August, 14, 2026 Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euro
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining
Lyon (France), August 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
Ventes totales de produits de 64,0 millions d'euros o En ligne avec les attentes; confirmation de la
Lyon (France), July 22, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine c
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Dr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 –
Lyon (France), June 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co
Lyon (France), May 28, 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co
Lyon (France), le 28 mai 2026 - Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée
Valneva NASDAQ: VALN reported lower first-quarter revenue and a wider loss for 2026, while managemen
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
Lyon (France), May 13, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine co
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon